Drug Trial Radar · NCT00725985
Oral Cladribine in Early Multiple Sclerosis (MS)
Last checked: Nov 20, 2026Latest source record: Mar 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
617
Actual
Start
Dec 31, 2008
Primary completion
Jul 31, 2011
Study completion Apr 30, 2012
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, clinical trial to assess the safety and efficacy of two doses of oral cladribine versus placebo in participants who had a first clinical demyelinating event (clinically isolated syndrome). Participants in either the cladribine or placebo group may also enter treatment periods with open-label interferon-beta or open-label cladribine depending upon the disease status. The primary objective of this study is to evaluate the effect of two dosage regimens of oral cladribine versus placebo on the time to conversion to multiple sclerosis (MS) (from randomization) according to the Poser criteria in participants with first clinical demyelinating event at high risk of converting to MS.
Conditions
- Multiple Sclerosis
Interventions
CladribineDrug
Cladribine tablets were administered until CDMS conversion, whichever occur first.
PlaceboDrug
Placebo matched to cladribine tablets were administered.
Rebif® new formulation (RNF)Drug
Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMSTime frame: ITP: Baseline up to Week 96
Locations
158 sites in 34 countries. Site status is shown where the registry gives one.
Hope Research Institute Medical Plaza LLC Desert Hills
Phoenix, Arizona
Multiple Sclerosis Center Drive, Neurology Suite 701
Newport Beach, California
University of Colorado at Denver Health Sciences
Denver, Colorado
Fort Collins Neurology
Fort Collins, Colorado
MS Center of Brevard MIMA Centry Research Associates
Melbourne, Florida
University of South Florida
Tampa, Florida
MS Center of Atlanta
Atlanta, Georgia
Bruce Hughes West Building
Des Moines, Iowa
Michigan Neurology Associates
Clinton Township, Michigan
Henry Ford Hospital
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Dennis Dietrich
Great Falls, Montana
University of Medicine and Dentistry of New Jersey School of Neurology
Stratford, New Jersey
Upstate Clinical Research LLC 3
Albany, New York
Neurological Specialists of Long Island
Great Neck, New York
Multiple Sclerosis Center of Northeastern NY
New York, New York
Comprehensive MS Care Clinic at South Shore Multiple Sclerosis
Patchogue, New York
Carolinas Medical Center
Charlotte, North Carolina
Meritcare Neuroscience Center Neurology
Fargo, North Dakota
University of Cincinnati
Cincinnati, Ohio
MS Center of Oklahoma
Oklahoma City, Oklahoma
Neurology and Sleep Medicine
Bethlehem, Pennsylvania
Swedish Medical Center Cherry Hill
Seattle, Washington
Neurology & Neurological Association of Tacoma
Tacoma, Washington
Instituto Medico Rodriguez Alfici
Godoy Cruz, Argentina
Fundacion Rosarina de Neurorehabilitacion
Rosario, Argentina
Krankenhaus der Barmherzigen Brüder
Linz, Austria
Algemeen Ziekenhuis St Jan
Bruges, Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
Hopital Erasme
Brussels, Belgium
CHU de Liege - Domaine Universitaire du Sart Tilman,
Liège, Belgium
Clinical Center University of Sarajevo
Sarajevo, Bosnia and Herzegovina
Military Medical Academy- Sofia (MMA)
Pleven, Bulgaria
MBAL Rousse AD 1st
Rousse, Bulgaria
Central Clinic Hospital
Sofia, Bulgaria
Military Medical Academy
Sofia, Bulgaria
National Heart Hospital
Sofia, Bulgaria
Second MHAT
Sofia, Bulgaria
Tokuda Hospital
Sofia, Bulgaria
University Hospital St Naum
Sofia, Bulgaria
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.